ArticleLaryngoscope investigative otolaryngology2025
Prevalence and Treatment of Dysphonia in Parkinson's Disease: A Cross-Sectional National Database Study.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Listening to the Mind: Integrating Vocal Biomarkers into Digital Health.Brain sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Around 89% of individuals with Parkinson's disease (PD) present with speech and voice disorders, but only 3%-4% receive speech treatment. Using the NIH All of Us Research Program, this study aims to report the prevalence of dysphonia, the incidence of speech evaluations and treatments, and potential disparities in PD patients on a national scale. Methods: ICD-9 and ICD-10 codes were used to identify individuals with PD and dysphonia in the All of Us database. Diagnostic voice care was determined using CPT codes for flexible laryngoscopy and speech evaluation, while treatment was based on CPT codes for vocal fold augmentation and speech therapy. Unadjusted and adjusted logistic regression analyses were conducted to evaluate the association between voice care access and demographic and socioeconomic factors. Results: Of 1968 PD patients, 257 (13.1%) had a concomitant diagnosis of dysphonia. 1683 patients (85.5%) received no voice care. Among those with voice care, 264 (13.4%) underwent a diagnostic evaluation and 124 (6.3%) received treatment. Based on adjusted logistic regression models, factors associated with decreased odds of voice care were female sex (aOR = 0.62, 95% CI = 0.45-0.85, Conclusion: PD commonly presents with voice disorders. Using a national database, only 13.1% of PD patients had a formal dysphonia diagnosis, and only 6.3% received speech treatment. Female sex and Hispanic ethnicity correlated with decreased voice care. This study suggests the underdiagnosis and undertreatment of dysphonia in PD.Level of Evidence: 3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.